Abstract
Malignant pleural mesothelioma (MPM) is a fatal cancer type that affects the membranes lining the lungs and is causally associated with asbestos exposure. Despite the effectiveness of conventional anti-cancer treatment, its prognosis remains very poor. We previously demonstrated a significant survival benefit for PD-L1 blockade in preclinical models of MPM. Data from preclinical studies in other tumour models show that anti-PD-L1 and anti-angiogenic therapy can enhance each other’s efficacy, thereby supporting the investigation of combined blockade of PD-L1 and VEGFR2 in MPM.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
